Group 1 - The core point of the article is that Boji Pharmaceutical's subsidiary has received approval for a clinical trial of a new drug, "Qingzhi Ointment," from the National Medical Products Administration [1] - As of January to June 2025, Boji Pharmaceutical's revenue composition shows that 99.46% comes from services, while other businesses account for 0.54% [1] - The current market capitalization of Boji Pharmaceutical is 3.9 billion yuan [1] Group 2 - The article also mentions that prior to the arrest of the chairman of Peking University Pharmaceutical, police had investigated the group's factory, indicating potential issues within the company [1] - Internal sources suggest that the group's assets have been disposed of by the chairman, with significant funds remaining unaccounted for [1]

Core Viewpoint - The approval of "Qingzhi Ointment" by the National Medical Products Administration marks a significant advancement for the company in the field of traditional Chinese medicine, potentially opening new market opportunities for innovative herbal treatments [1] Group 1: Product Development - The product "Qingzhi Ointment" is a new formulation based on traditional Chinese medicine principles, specifically designed for the treatment of knee osteoarthritis with symptoms of wind-cold-dampness [1] - It is classified as a Class 1 innovative traditional Chinese medicine, indicating its status as a new prescription that has not been marketed domestically or internationally [1] Group 2: Regulatory Approval - The full subsidiary of the company, Guangzhou Boji New Drug Clinical Research Center Co., Ltd., has successfully obtained the Clinical Trial Approval Notice from the National Medical Products Administration for "Qingzhi Ointment" [1] - This regulatory approval is a critical step in the drug development process, allowing the company to proceed with clinical trials [1]

Core Viewpoint - The announcement indicates that the company's subsidiary, Guangzhou Boji New Drug Clinical Research Center Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of "Qingzhi Ointment," a new traditional Chinese medicine formulation [1] Group 1 - "Qingzhi Ointment" is a new prescription formulation based on traditional Chinese medicine theory and is classified as a Class 1 innovative traditional Chinese medicine [1] - The ointment is intended for the treatment of knee osteoarthritis with symptoms of wind-cold-dampness, focusing on dispelling wind, eliminating dampness, relieving cold, promoting circulation, and alleviating pain [1]

Core Viewpoint - The announcement by Boji Pharmaceutical (300404.SZ) regarding the approval of "Qingzhi Ointment" for clinical trials by the National Medical Products Administration indicates a step forward in the company's drug development efforts, although it is not expected to significantly impact the company's financial performance in the short term [1]. Group 1: Drug Development - Boji Pharmaceutical's wholly-owned subsidiary, Guangzhou Boji New Drug Clinical Research Center Co., Ltd., has received the clinical trial approval for "Qingzhi Ointment," classified as a Class 1 innovative traditional Chinese medicine [1]. - The ointment is intended for the treatment of knee osteoarthritis with symptoms of wind-cold-dampness, focusing on dispelling wind, overcoming dampness, relieving cold, promoting circulation, and alleviating pain [1]. Group 2: Financial Impact - The company stated that the approval of the drug will not have a significant impact on its operating performance [1]. - The company will fulfill its information disclosure obligations based on the progress of the drug development [1]. Group 3: R&D Uncertainties - The company acknowledged the long development cycle and multiple stages involved in drug research and development, highlighting the inherent uncertainties in the process [1].

"卿芷软膏"为多味饮片在中医药理论指导下组方而成的制剂，属于未在境内外上市的中药新处方制剂， 为1.1类中药创新药。本药品用于膝骨关节炎风寒湿痹证，主治祛风胜湿，散寒通络，行气止痛。 博济医药（300404）(300404.SZ)发布公告，近日，公司全资子公司广州博济新药临床研究中心有限公 司申报的"卿芷软膏"获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。 ...

人民财讯11月11日电，博济医药（300404）11月11日公告，公司全资子公司广州博济新药临床研究中心 有限公司申报的"卿芷软膏"获得国家药监局核准签发的《药物临床试验批准通知书》。"卿芷软膏"为多 味饮片在中医药理论指导下组方而成的制剂，属于未在境内外上市的中药新处方制剂，为1.1类中药创 新药。该药品用于膝骨关节炎风寒湿痹证，主治祛风胜湿，散寒通络，行气止痛。 ...

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Guangzhou Boji New Drug Clinical Research Center Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of "Qingzhi Ointment," which is aimed at treating knee osteoarthritis [1] Group 1 - The drug name is Qingzhi Ointment, and it is classified as a traditional Chinese medicine under category 1.1 [1] - The approval notification number is 2025LP02962 [1]

智通财经APP讯，博济医药(300404.SZ)发布公告，近日，公司全资子公司广州博济新药临床研究中心有 限公司申报的"卿芷软膏"获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。 "卿芷软膏"为多味饮片在中医药理论指导下组方而成的制剂，属于未在境内外上市的中药新处方制剂， 为1.1类中药创新药。本药品用于膝骨关节炎风寒湿痹证，主治祛风胜湿，散寒通络，行气止痛。 ...

3、适应症：膝骨关节炎 4、注册分类：中药 1.1 类 关于子公司获得药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，博济医药科技股份有限公司（以下简称"公司"）全资子公司广州博 济新药临床研究中心有限公司申报的"卿芷软膏"获得国家药品监督管理局核准 签发的《药物临床试验批准通知书》。现将相关情况公告如下： 一、 药物基本情况 1、通知书编号：2025LP02962 2、药品名称：卿芷软膏 证券代码：300404 证券简称：博济医药 公告编号：2025-082 博济医药科技股份有限公司 5、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 2025 年 8 月 22 日受理的卿芷软膏符合药品注册的有关要求，在进一步完善临床 试验方案的基础上，同意本品开展用于膝骨关节炎的临床试验。 二、 药物其他情况 露义务。由于药品研发的特殊性，药品从临床试验到获准上市的周期长、环节多， 易受到诸多不可预测的因素影响，临床试验进度及结果、未来产品市场竞争形势 等均存在不确定性。 "卿芷软膏"为多味饮片在中医药理论指导下组方而成 ...

Core Insights - Boji Pharmaceutical is a leading provider of new drug research and development outsourcing services in China, established in 2002 and listed on the Shenzhen Stock Exchange in 2015 [1] Group 1: Business Overview - Boji Pharmaceutical offers comprehensive new drug R&D services, including preclinical research, clinical research, technology transfer, and consulting services [1] - The company operates in the pharmaceutical and biotechnology sector, specifically in medical services and R&D outsourcing, with relevant concepts including Helicobacter pylori and hepatitis treatment [1] Group 2: Financial Performance - For Q3 2025, Boji Pharmaceutical reported revenue of 584 million yuan, ranking 16th out of 29 in the industry, significantly lower than the top competitor WuXi AppTec at 32.857 billion yuan [2] - The net profit for the same period was 23.8675 million yuan, placing the company 21st in the industry, again far behind WuXi AppTec's 12.206 billion yuan [2] Group 3: Financial Ratios - As of Q3 2025, Boji Pharmaceutical's debt-to-asset ratio was 33.62%, higher than the previous year's 31.81% and above the industry average of 22.79% [3] - The gross profit margin was 28.83%, down from 32.19% year-on-year and below the industry average of 37.70% [3] Group 4: Leadership and Shareholder Information - The chairman and controlling shareholder, Wang Tingchun, saw his salary decrease from 414,000 yuan in 2023 to 391,000 yuan in 2024 [4] - As of September 30, 2025, the number of A-share shareholders increased by 18.91% to 29,600, while the average number of circulating A-shares held per shareholder decreased by 15.21% [5] Group 5: Business Developments - Clinical business showed stable growth with clinical research service revenue of 290 million yuan and new contract value of 752 million yuan, achieving a business gross margin of 30.6% [5] - Non-clinical business performance varied, with preclinical research service revenue at 40.87 million yuan and other consulting services at 23.49 million yuan [5] - The company has made progress in self-developed projects, including innovative traditional Chinese medicine [5]